Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging

Authors: Jon-Vidar Gaustad, Trude G. Simonsen, Ragnhild Smistad, Catherine S. Wegner, Lise Mari K. Andersen, Einar K. Rofstad

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect.

Methods

A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K trans (the volume transfer constant of Gd-DOTA) and v e (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data.

Results

Untreated A-07 tumors showed higher K trans, v e, and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K trans, i.e., K trans was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K trans values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K trans, whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K trans. In R-18 tumors, significant changes in K trans were not observed. Treatment induced changes in tumor size, v e, and ADC were not seen in any of the tumor lines.

Conclusions

Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI.
Appendix
Available only for authorised users
Literature
1.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4–6.CrossRefPubMed
2.
3.
Jia Y, Liu M, Huang W, Wang Z, He Y, Wu J, et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res. 2012;18(2):315–23.PubMedCentralCrossRefPubMed
4.
Gaustad JV, Simonsen TG, Andersen LM, Rofstad EK. Thrombospondin-1 domain-containing peptide properdistatin improves vascular function in human melanoma xenografts. Microvasc Res. 2015;98:159–65.CrossRefPubMed
5.
Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13(13):3942–50.CrossRefPubMed
6.
Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006;66(7):3639–48.CrossRefPubMed
7.
Roskoski Jr R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356(2):323–8.CrossRefPubMed
8.
Morgan B, Horsfield MA, Steward WP. The role of imaging in the clinical development of antiangiogenic agents. Hematol Oncol Clin North Am. 2004;18(5):1183–206.CrossRefPubMed
9.
Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66(24):11520–39.CrossRefPubMed
10.
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58(7):1408–16.PubMed
11.
Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer. 2012;12(1):388.PubMedCentralCrossRefPubMed
12.
Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13(11):3395–402.PubMedCentralCrossRefPubMed
13.
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553–63.PubMed
14.
Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging. 2012;35(4):745–63.CrossRefPubMed
15.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–32.CrossRefPubMed
16.
Yankeelov TE, Arlinghaus LR, Li X, Gore JC. The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. Semin Oncol. 2011;38(1):16–25.PubMedCentralCrossRefPubMed
17.
Padhani AR. Diffusion magnetic resonance imaging in cancer patient management. Semin Radiat Oncol. 2011;21(2):119–40.CrossRefPubMed
18.
O’Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012;9(3):167–77.CrossRefPubMed
19.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–23.PubMedCentralCrossRefPubMed
20.
Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D, et al. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Neoplasia. 2012;14(1):54–64.PubMedCentralCrossRefPubMed
21.
Gaustad JV, Pozdniakova V, Hompland T, Simonsen TG, Rofstad EK. Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts. J Exp Clin Cancer Res. 2013;32:93.PubMedCentralCrossRefPubMed
22.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.CrossRefPubMed
23.
Rofstad EK. Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. Br J Cancer. 1994;70(5):804–12.PubMedCentralCrossRefPubMed
24.
Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med. 1994;31(5):567–71.CrossRefPubMed
25.
Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev. 2009;3(2):91–107.PubMedCentralCrossRefPubMed
26.
Benjaminsen IC, Graff BA, Brurberg KG, Rofstad EK. Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts. Magn Reson Med. 2004;52(2):269–76.CrossRefPubMed
27.
Rofstad EK, Halsør EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 2000;60(17):4932–8.PubMed
28.
Tufto I, Lyng H, Rofstad EK. Vascular density in human melanoma xenografts: relationship to angiogenesis, perfusion and necrosis. Cancer Lett. 1998;123(2):159–65.CrossRefPubMed
29.
Tufto I, Rofstad EK. Interstitial fluid pressure, fraction of necrotic tumor tissue, and tumor cell density in human melanoma xenografts. Acta Oncol. 1998;37(3):291–7.CrossRefPubMed
30.
Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91–101.CrossRefPubMed
31.
Bjørnæs I, Rofstad EK. Microvascular permeability to macromolecules in human melanoma xenografts assessed by contrast-enhanced MRI--intertumor and intratumor heterogeneity. Magn Reson Imaging. 2001;19(5):723–30.CrossRefPubMed
32.
Graff BA, Benjaminsen IC, Brurberg KG, Ruud EB, Rofstad EK. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. J Magn Reson Imaging. 2005;21(3):272–81.CrossRefPubMed
33.
Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, Rofstad EK. Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. Neoplasia. 2008;10(4):354–62.PubMedCentralCrossRefPubMed
34.
Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007;67(20):9921–8.CrossRefPubMed
35.
O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015;21(2):249–57.CrossRefPubMed
36.
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
37.
Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Maelandsmo GM et al. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging. 2013;38(5):1043-53.
38.
Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72(2):402-7.
Metadata
Title
Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
Authors
Jon-Vidar Gaustad
Trude G. Simonsen
Ragnhild Smistad
Catherine S. Wegner
Lise Mari K. Andersen
Einar K. Rofstad
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1918-1

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

A seven-gene CpG-island methylation panel predicts breast cancer progression

Research article

Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models

Debate

Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential

Research article

Prognostic significance of classified extramural tumor deposits and extracapsular lymph node invasion in T3–4 colorectal cancer: a retrospective single-center study

Research article

Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells

Research article

Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits